VBI Vaccines Inc. (VBIV)

0,5740 -0,0254 (-4,24%) Alla chiusura: 04:00PM EDT

VBI Vaccines Inc.

160 Second Street
Floor 3
Cambridge, MA 02142
United States
617 830 3031
https://www.vbivaccines.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 131

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Jeffery R. Baxter FCMA	President, CEO & Director	908,06k	N/D	1961
Dr. David Evander Anderson	Chief Scientific Officer	534,25k	N/D	1970
Dr. Francisco Diaz-Mitoma FRCPC, M.D., Ph.D.	Chief Medical Officer	544,52k	N/D	1955
Ms. Nell Beattie	CFO, Head of Corporate Development & Director	N/D	N/D	1988
Nicole Anderson	Director of Corporate Communications & Investor Relations	N/D	N/D	N/D
Ms. Athena Kartsaklis	Senior VP of Finance, Chief Compliance Officer & Principal Financial Officer	N/D	N/D	1965
Mr. Avi Mazaltov	Global Head of Manufacturing & GM of SciVac	N/D	N/D	1962
Mr. Misha Nossov	Senior VP of Global Commercial Supply Strategy & Head of Europe	N/D	N/D	N/D
Mr. T. Adam Buckley	Senior Vice President of Business Development	N/D	N/D	1976
Mr. John Robert Dillman	Chief Commercial Officer	N/D	N/D	1968

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di VBI Vaccines Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.